Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis.
Lorenzo Vittorio RindiDrieda ZaceNeva BraccialargheBarbara MassaVirginia BarchiRoberta IannazzoIlenia FatoFrancesco De MariaDimitra KontogiannisVincenzo MalagninoLoredana SarmatiMarco IannettaPublished in: Drug safety (2024)
A higher risk of drug-related PML in patients whose immune system is not additionally depressed by means of neoplasms, HIV or concomitant medications is found in the neurological field. This risk is higher in MS treatment, and specifically during long-term natalizumab therapy. While this drug is still routinely prescribed in this field, considering the efficacy in reducing MS relapses, in other areas it could play a smaller role, and be gradually replaced by other safer and more recently approved agents.
Keyphrases
- drug induced
- multiple sclerosis
- liver injury
- mass spectrometry
- end stage renal disease
- adverse drug
- newly diagnosed
- ms ms
- chronic kidney disease
- ejection fraction
- hiv infected
- antiretroviral therapy
- hepatitis c virus
- peritoneal dialysis
- hiv positive
- emergency department
- south africa
- mesenchymal stem cells
- combination therapy
- blood brain barrier
- smoking cessation